Novo Holdings, the investment company controlled by Novo Nordisk’s largest shareholder, is backing an Italian startup accelerator and fund aimed at fostering early-stage life-science companies. Bloomberg reports that the effort is part of a broader strategy by Novo Holdings to invest beyond Denmark and strengthen European life-sciences hubs. The initiative targets drug startups and focuses on supporting their early development. The Next Web describes the move as an extension of a pattern in which Novo Holdings has previously directed capital into life-science and deep-tech investment vehicles outside Copenhagen. While the outlets emphasize the geographic shift toward Italy, both accounts present the same core information: Novo Holdings is providing support through a new fund/accelerator to help build a pipeline of Italian drug and life-science startups. The reporting does not describe specific deal terms, funding size, or the name and structure of the accelerator in the provided excerpts. It also does not provide details on which companies will be selected. Overall, the coverage links the investment to Novo Holdings’ wider role in backing European innovation ecosystems beyond its Danish base.